Copyright
©2008 The WJG Press and Baishideng.
World J Gastroenterol. Jun 14, 2008; 14(22): 3549-3553
Published online Jun 14, 2008. doi: 10.3748/wjg.14.3549
Published online Jun 14, 2008. doi: 10.3748/wjg.14.3549
Table 1 General information and medication status
| Case | Age (yr) | Hepatitis history (yr) | Current diagnosis | Medication history | Telbivudine | Drug and time combined | |
| Dosage | Time (mo) | ||||||
| 1 | 45 | 10 | Hepatocirrhosis | DLAM, ECV | 600 mg bid | 2 | - |
| 600 mg qd | 5 | ADV for 5 mo | |||||
| 2 | 35 | 6 | Hepatitis B | LAM, ADV | 600 mg qd | 7 | Interferon for 3 mo |
| 3 | 37 | 37 | Hepatitis B | LAM, ADV | 600 mg qd | 1 | - |
| 4 | 30 | 1 | Hepatitis B | - | 600 mg qd | 7 | Interferon for 3 mo |
| 5 | 25 | 2 | Hepatitis B | ADV | 600 mg qd | 9 | Interferon for 3 mo |
- Citation: Zhang XS, Jin R, Zhang SB, Tao ML. Clinical features of adverse reactions associated with telbivudine. World J Gastroenterol 2008; 14(22): 3549-3553
- URL: https://www.wjgnet.com/1007-9327/full/v14/i22/3549.htm
- DOI: https://dx.doi.org/10.3748/wjg.14.3549